Cerebrolysin Overview, Dosing & Safety | Peptide Database

Cerebrolysin (Cerebrolysin®)

Neuropeptide Preparation | Neurological Recovery

Community Research

Join others researching Cerebrolysin — share findings, ask questions, and learn from real experiences

Standardized neuropeptide preparation containing bioactive peptides and amino acids exhibiting neurotrophic and neuroprotective properties for stroke recovery, traumatic brain injury, and cognitive enhancement. Used clinically in 50+ countries.

IV/IM administration provides optimal bioavailability and brain penetration of neuropeptides and neurotrophic factors.

Molecular Data

Complex or non-standard sequence format

Research Indications

Meta-analyses show modest cognitive improvements, though clinical significance remains debated.

Multiple RCTs demonstrate significant ADAS-cog and CIBIC+ improvements.

Large meta-analysis shows significant NIHSS improvements; other studies found no functional benefit.

Largest meta-analysis (1,879 patients) shows NIHSS benefits; independent analysis found no mRS improvement.

Multiple trials including CAPTAIN series confirm GCS/GOS improvements.

Pilot trial shows promising 6-month outcomes; requires larger confirmatory studies.

Some studies show enhanced recovery; results vary significantly between trials.

Early administration within 72 hours shows better outcomes than delayed treatment.

Dosing Protocols

Primary administration route with well-established protocols for direct brain delivery via IV/IM.

Small Volume IV

Up to 10mL

Once daily

Undiluted IV slow push over 3 minutes

Intramuscular

Up to 5mL

Undiluted IM injection over 3 minutes

Acute Stroke

20-50mL

Once daily for 10-21 days

IV infusion (diluted to 100mL minimum)

Traumatic Brain Injury

Once daily for 7-30 days

Alzheimer's Disease

10-30mL

5 days weekly for 4 weeks

IV injection/infusion (2-4 cycles yearly)

Vascular Dementia

Reconstitution Instructions

Cerebrolysin ampoules (5, 10, or 20 mL)

Saline, Ringer solution, or 5% glucose (minimum 100 mL for infusion)

Disposable one-way IV infusion sets and cannulas

Sterile syringes and alcohol swabs

1 Break ampoule and extract Cerebrolysin immediately before use

2 For direct injection: Up to 10 mL IV undiluted (slow 3 minutes) or 5 mL IM

3 For infusion: Dilute 10-50 mL to minimum 100 mL with compatible solution

4 Start infusion immediately after dilution—infuse within 15 minutes

5 Flush IV catheter with sodium chloride before and after administration

6 Use disposable one-way infusion sets; discard after use

Interactions

What to Expect

Side Effects & Safety

Common Side Effects

Generally well tolerated

Possible mild dizziness or agitation in early treatment

Stop Signs - Discontinue if:

Severe allergic reactions (anaphylaxis, severe rash)

New onset seizure activity

Significant cardiovascular events during administration

Severe renal dysfunction or worsening kidney function

Contraindications

Epilepsy

Severe renal insufficiency

History of severe allergic reactions to porcine products

Quality Checklist

Good Signs

Clear amber solution from reputable source

Room temperature storage ≤25°C

Protected from light in original carton

Authorized EVER Pharma distributor

Warning Signs

Some published studies have been retracted due to research misconduct; rely on independent meta-analyses

Bad Signs

Frozen product or improper storage—never freeze

Mixing with incompatible solutions (amino acids, vitamins, cardiovascular medications)

Frequently Asked Questions

Does Cerebrolysin actually work for stroke recovery or is the evidence mixed?

Evidence is mixed. Large meta-analysis of 1,879 stroke patients showed NIHSS (neurological function) superiority, but an independent analysis found no significant improvement in modified Rankin Scale (functional outcomes). Cerebrolysin appears to have early neurological benefits without clear long-term functional recovery advantage.

Is Cerebrolysin safe given some published studies have been retracted?

Yes, several Cerebrolysin studies were retracted due to research misconduct. However, well-conducted meta-analyses by independent researchers confirm safety and modest efficacy signals. Rely on meta-analyses and well-designed RCTs rather than individual studies, some of which have credibility issues.

How quickly should Cerebrolysin be started after stroke or TBI for best results?

Early administration within 72 hours shows better outcomes than delayed treatment. Acute stroke protocols use 20-50mL daily IV infusion for 10-21 days. TBI protocols use similar dosing for 7-30 days depending on severity. Earlier initiation appears critical for neuroprotective benefit.

Can I mix Cerebrolysin with other IV solutions, vitamins, or medications?

No. Official guidelines contraindicate mixing Cerebrolysin with amino acid solutions, cardiovascular medications, or vitamin solutions in the same IV infusion. Compatibility issues exist, so use dedicated IV lines. Flush with sodium chloride before and after administration per protocol.

References

Phase IIIb/IV RCT: patients with GCS 7-12 received 50 mL Cerebrolysin daily for 10 days + two additional 10 mL cycles; confirmed beneficial effects on overall outcome after moderate-severe TBI.

Meta-analysis of 1,879 stroke patients showed NIHSS superiority of Cerebrolysin (MW 0.60, P < 0.0001); NNT = 7.7 for clinically relevant early neurological improvement.

Meta-analysis of 1,779 patients found no significant benefit on mRS response (RR 1.33, P=0.28) or Barthel Index; concluded routine use for long-term stroke rehabilitation not supported.

10 studies of 8,749 TBI patients; GOS improvement was statistically significant (mean difference 0.422, P = 0.000); mortality and length of stay were not significantly affected.

6 RCTs in mild-to-moderate AD; Cerebrolysin significantly superior to placebo on ADAS-cog at 4 weeks (SMD -0.40, P=0.003) and CIBIC global clinical change at 4 weeks and 6 months.

Disclaimer

This information is for educational and research purposes only. Consult a healthcare professional before use.